GlobeNewswire

Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK(TM) (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

Del
  • Study met primary endpoint (p=0.0033)
  • Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB)
  • Company plans to pursue regulatory approvals with FDA and EMA

RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today data from its Phase 3 SIOPEL 6 study presented during the late breaker session on Saturday, October 14, 2017 at SIOP 2017 in Washington, DC.

Top Line Efficacy Data

The SIOPEL 6 study met its primary endpoint.  The study demonstrated that the addition of STS significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumour protection. Among the 99 evaluable patients, hearing loss occurred in 30/45=67% treated with Cisplatin (Cis) alone and in 20/54=37.0% treated with Cis+STS, corresponding to a relative risk of 0.56(P=0.0033).

Fennec plans to pursue regulatory approval for PEDMARKTM based on the data from the SIOPEL 6 study along with the proof of principle data from COG ACCL0431. STS has received Orphan Drug Designation in the US in this setting and plans to pursue European Market Exclusivity for Pediatric Use upon approval.

"I am absolutely delighted that after 30 years of research we have found a safe way to reduce ototoxicity in children receiving platinum containing chemotherapy," said Penelope Brock, M.D., PhD, International Chair of SIOPEL. "This means that children who are cured from cancer after receiving platinum treatment can look forward to a normal healthy life, fully integrated into society. I believe this marks a new standard of care in pediatric oncology."

The Company also reported top-line data for secondary endpoints Event Free Survival (EFS) and Overall Survival (OS). The combination of Cis+STS was generally well tolerated. With a follow up of 52 months, 3yr EFS is Cis 78.8% and Cis+STS 82.1%; 3yr OS is Cis 92.3% and Cis+STS 98.2%.

"We are very pleased with the results of this study," stated Rosty Raykov, CEO of Fennec. "We would like to thank all the patients and their families who participated in this trial, physicians, the entire SIOPEL 6 team, and Dr. Neuwelt and his research team at OHSU. We believe that if approved PEDMARK would be an important therapy for patients and caregivers where currently there are no treatment options."

Safety and Tolerability

In the study, the results presented showed that treatment was well tolerated and acute toxicity similar and expected between arms. The table below presents the toxicities of the two arms: 

Adverse event Grade CIS   CIS+STS  
    N % N %
Febrile neutropenia

3 7 13.5 5 8.8
4 - - - -
Infection

3 5 9.6 6 10.5
4 - - - -
Hypomagnesemia

3 1 1.9 1 1.8
4 - - - -
Hypernatremia

3 - - 1 1.8
4 - - - -
Vomiting

3 1 1.9 3 5.3
4 - - - -
Nausea

3 3 5.8 2 3.5
4 - - - -

SIOP 2017 Presentation

Fennec will provide access to the recording of SIOP 2017 late breaker presentation on the Company's website.

To access the archived recording, visit the Fennec website at www.fennecpharma.com.

SIOPEL 6

SIOPEL 6 is a multi-centre open label randomized phase 3 study evaluating the efficacy of STS in reducing ototoxicity in patients receiving cisplatin monotherapy for standard risk hepatoblastoma.  From the beginning of 2007 to the end 2014, 52 sites from 11 countries enrolled 113 evaluable patients.  The study is closed to recruitment and all protocol pre-specified IDMC safety reviews are now complete.  The primary efficacy hearing endpoint analysis can be performed once patients have reached 3.5 years of age and an audiometry test can be carried out. The SIOPEL 6 study trial was designed with 80% power and a 5% significance level to detect an absolute 25% reduction in the rate of Brock grade greater than or equal to 1 hearing loss with a chi-square test, from a 60% hearing loss in Cis alone arm to a 35% hearing loss in Cis+STS arm. The primary endpoint is the rate of Brock grade greater than or equal to 1 hearing loss determined after the end of treatment at the age of greater than or equal to 3.5 years by pure tone audiometry.

About PEDMARKTM (sodium thiosulfate/STS)

Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies.  Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.

In the U.S. and Europe there is estimated that over 7,000 children are diagnosed with local cancers that may receive platinum-based chemotherapy. Localized cancers that receive platinum agents may have overall survival rates of greater than 80% further emphasizing the quality of life after treatment. The incidence of hearing loss in these children depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

STS has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma.  SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors. COG ACCL0431 final results were published in the Lancet Oncology.

In May 2017, Fennec announced the launch of a Named Patient Program in Europe. European based Healthcare Professionals can obtain details about STS Named Patient Program by emailing clinical@fennecpharma.com.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the US in this setting. Fennec has an exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.

Forward looking statements

Except for historical information described in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2016. Fennec Pharmaceuticals, Inc. disclaims any obligation to update these forward-looking statements except as required by law.

The scientific information discussed in this news release related to PEDMARKTM is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, Health Canada or other regulatory and no conclusions can or should be drawn regarding the safety or effectiveness of such product candidate.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

For further information, please contact:

Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Fennec Pharmaceuticals via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

CEO confidence in growth dips dramatically21.1.2019 18:45Pressemelding

Uncertainty in global economic growth in almost all countries, caution prevails US remains key target market for growth with China narrowing the gap, both see a decline from 2018 Trade conflicts, policy uncertainty, geopolitical issues and skills gap impacting strength of global economy and growth DAVOS, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- What a difference a year makes. Nearly 30% of business leaders believe that global economic growth will decline in the next 12 months, approximately six times the level of 5% last year – a record jump in pessimism. This is one of the key findings of PwC’s 22nd annual survey of 1,300 plus CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. This is in vivid contrast to last year’s record jump, 29% to 57%, in optimism about global economic growth prospects. Although, all is not doom and gloom: 42% still see an improved economic outlook, though this is down significantly from a high of 57% in 2018. Overal

Komet announces initial Mineral Resource Estimate for the Kabaya Prospect, (Dabia Sud property, Mali)21.1.2019 15:10Pressemelding

QUEBEC CITY, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Komet Resources inc. (TSX-V: KMT) (“Komet” or the “Company”) is pleased to report an initial mineral resource estimate for the Kabaya gold prospect drill prospect, located in the southern part of its Dabia Sud exploration permit (“the Property”) in Western Mali, West Africa. Highlights of the Resource Estimate include : An Indicated Resource of 3.17 million tonnes (Mt) grading 1.03 g/t for 105,000 contained gold ounces and an Inferred Resource of 0.96 Mt grading 1.14 g/t for 35,000 contained gold ounces at a cut-off grade of 0.40 g/t Au (table 1). The pit constrained resource is based on optimized pit shells using a gold price of 1350 US$ and a presumed heap leach gold recovery of saprolite ore. Gold mineralization at Kabaya remains open at depth in bedrock and laterally to the south-west and north-west. Komet intends to continue the resource definition drilling program in order to further develop the resource laterally in saprolite and at

INVNT Expands Global Footprint With Singapore Launch21.1.2019 15:07Pressemelding

NEW YORK, NY, Jan. 21, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, today announces the opening of its second office in the APAC region – and eighth office globally – located in the thriving creative hub of Singapore. The move comes as the agency, which made its foray into the APAC region in October 2017 with launch of an office in Sydney, Australia, secures global contracts with a number of both new and existing clients. In the last 12 months, INVNT has achieved a 70% client retention rating and worked with 23 new clients worldwide. "The global demand for live events is continually on the rise, with more and more organizations elevating “live” as a core part of their marketing, sales and public relations strategies. At INVNT we believe in the power of live brand storytelling™, as it enables our clients to create deeper, more meaningful relationships with their target audiences,” said Scott Cullather, CEO, INVNT. "With businesses benefitting from the posi

INVNT Expands Global Footprint With Singapore Launch21.1.2019 15:06Pressemelding

NEW YORK, NY, Jan. 21, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, today announces the opening of its second office in the APAC region – and eighth office globally – located in the thriving creative hub of Singapore. The move comes as the agency, which made its foray into the APAC region in October 2017 with launch of an office in Sydney, Australia, secures global contracts with a number of both new and existing clients. In the last 12 months, INVNT has achieved a 70% client retention rating and worked with 23 new clients worldwide. "The global demand for live events is continually on the rise, with more and more organizations elevating “live” as a core part of their marketing, sales and public relations strategies. At INVNT we believe in the power of live brand storytelling™, as it enables our clients to create deeper, more meaningful relationships with their target audiences,” said Scott Cullather, CEO, INVNT. "With businesses benefitting from the posi

Tenaris completes acquisition of significant stake in Saudi Steel Pipe Company21.1.2019 13:57Pressemelding

LUXEMBOURG, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announced today that it closed its previously-announced acquisition from a private group of 47.79% of the shares of Saudi Steel Pipe Company (“SSP”), a welded steel pipes producer listed on the Saudi stock market, for a total amount of SAR 529.8 million (approximately US$141 million). SSP’s facilities are located in the Eastern Province of the Kingdom of Saudi Arabia and have a manufacturing capacity of 360,000 tons per year. The company, which started its operations in 1980 and serves energy, industrial and commercial segments, is qualified to supply products with major national oil companies in the region, including Saudi Aramco. Upon the closing of the transaction, four Tenaris’s nominees were appointed as new members of SSP’s board of directors. In addition, SSP’s board of directors appointed Mariano Armengol, a senior executive with Tenaris, as managing director and ch

FocusCura subsidiary Luscii will continue as independent company with partner OMRON Healthcare to accelerate their international expansion21.1.2019 12:37Pressemelding

Joining forces supports hospitals in moving care towards the home AMSTERDAM, The Netherlands, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Luscii, the e-health application for remote monitoring developed by FocusCura, is set to continue as an independent company. Healthcare entrepreneur and FocusCura founder Daan Dohmen has acquired the majority of the shares and formed a strategic partnership with OMRON Healthcare, known among other things as the largest manufacturer of blood pressure monitors in the world. Part of this cooperation includes an investment, with which Luscii can accelerate its development further in the coming years. OMRON will also support launches in more European countries, as the two companies announced today. Remote monitoring With Luscii, chronically ill patients can be monitored remotely. Remote monitoring via the Luscii app, in combination with smart algorithms, warns the patient's healthcare network in the event of a deteriorating health situation. Direct contact is then